Wird geladen...
First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (1, 2). Resistance to...
Gespeichert in:
| Veröffentlicht in: | Front Oncol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5932412/ https://ncbi.nlm.nih.gov/pubmed/29755953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00094 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|